See more : BF Investment Limited (BFINVEST.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Morgan Group Holding Co. (MGHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Morgan Group Holding Co., a leading company in the Financial – Capital Markets industry within the Financial Services sector.
You may be interested
- Anhui Tongfeng Electronics Company Limited (600237.SS) Income Statement Analysis – Financial Results
- New World Department Store China Limited (0825.HK) Income Statement Analysis – Financial Results
- Gridiron BioNutrients, Inc. (GMVP) Income Statement Analysis – Financial Results
- PAVmed Inc. (PAVMW) Income Statement Analysis – Financial Results
- John Bean Technologies Corporation (JBT) Income Statement Analysis – Financial Results
Morgan Group Holding Co. (MGHL)
Industry: Financial - Capital Markets
Sector: Financial Services
Website: https://morgangroupholdingco.com
About Morgan Group Holding Co.
Morgan Group Holding Co., through its subsidiary G.research, LLC provides institutional research and securities brokerage services in the United States. The company publishes research on approximately 100 companies with an emphasis on small and mid-cap investment. It also provides syndicated underwriting services. The company serves institutional clients and mutual funds, asset managers, private wealth management clients, and retail customers. Morgan Group Holding Co. was incorporated in 2001 and is based in Rye, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.14M | 2.01M | 2.97M | 4.44M | 9.25M | -12.08M | 15.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 101.17M | 128.37M |
| Cost of Revenue | 1.98M | 1.92M | 2.95M | 4.55M | 9.67M | 12.18M | 0.00 | 0.00 | 572.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 93.93M | 119.90M |
| Gross Profit | 157.13K | 87.74K | 28.68K | -117.46K | -427.50K | -24.26M | 15.68M | 0.00 | -572.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.24M | 8.47M |
| Gross Profit Ratio | 7.35% | 4.36% | 0.96% | -2.65% | -4.62% | 200.78% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7.15% | 6.60% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 835.85K | 1.03M | 1.60M | 1.52M | 1.98M | 57.81K | 55.12K | 56.90K | 64.61K | 108.59K | 62.69K | 145.08K | 0.00 | 31.31K | 29.56K | 36.75K | 2.98K | 4.00K | 3.00K | 2.00K | 35.00K | 64.00K | 0.00 | 0.00 |
| Selling & Marketing | 1.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.15M | 1.03M | 1.60M | 1.52M | 1.98M | 57.81K | 55.12K | 56.90K | 64.61K | 108.59K | 62.69K | 145.08K | 67.88K | 31.31K | 29.56K | 36.75K | 2.98K | 4.00K | 3.00K | 2.00K | 35.00K | 64.00K | 8.23M | 9.44M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.10M | 1.07M |
| Operating Expenses | 2.15M | 1.03M | 1.60M | 1.52M | 1.98M | 57.81K | 55.12K | 56.90K | 64.61K | 108.59K | 62.69K | 145.08K | 67.88K | 31.31K | 29.56K | 36.75K | 2.98K | 4.00K | 3.00K | 2.00K | 35.00K | 64.00K | 9.33M | 10.51M |
| Cost & Expenses | 2.98M | 2.95M | 4.54M | 6.07M | 11.65M | 57.81K | 55.12K | 56.90K | 64.61K | 108.59K | 62.69K | 145.08K | 67.88K | 31.31K | 29.56K | 36.75K | 2.98K | 4.00K | 3.00K | 2.00K | 35.00K | 64.00K | 103.26M | 130.41M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.07K | 216.00 | 191.00 | 2.00 | 2.00 | 5.12K | 745.00 | 925.00 | 346.00 | 864.00 | 8.88K | 19.94K | 19.00K | 10.00K | 4.00K | 3.00K | 6.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.07K | 216.00 | 191.00 | 2.00 | 2.00 | 5.12K | 745.00 | 925.00 | 346.00 | 864.00 | 8.88K | 19.94K | 19.00K | 10.00K | 4.00K | 3.00K | 6.00K | 273.00K | 310.00K |
| Depreciation & Amortization | 7.68K | 10.93K | 11.21K | 11.38K | 11.38K | 9.61K | 2.45M | 22.82K | 572.00 | 654.00 | 654.00 | 82.00 | -7.36K | -42.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.10M | 1.07M |
| EBITDA | -835.39K | -928.89K | -1.56M | -1.62M | -2.40M | -26.39M | -55.12K | -56.90K | -64.04K | -105.66K | -61.16K | -142.90K | -59.60K | 0.00 | -28.69K | -27.87K | 16.96K | 15.00K | 7.00K | 2.00K | -35.00K | -64.00K | -994.00K | -861.00K |
| EBITDA Ratio | -39.10% | -46.18% | -52.42% | -36.57% | -25.92% | 0.48% | -0.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.98% | -0.67% |
| Operating Income | -843.07K | -939.83K | -1.57M | -1.63M | -2.41M | -57.81K | -55.12K | -56.90K | -64.61K | -108.59K | -62.69K | -145.08K | -67.88K | -31.31K | -29.56K | -36.75K | -2.98K | -4.00K | -3.00K | -2.00K | -35.00K | -64.00K | -2.09M | -2.04M |
| Operating Income Ratio | -39.46% | -46.72% | -52.80% | -36.82% | -26.04% | 0.48% | -0.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2.07% | -1.59% |
| Total Other Income/Expenses | -4.76K | -786.67K | -803.59K | -1.11M | -1.30M | -1.31M | 216.00 | 191.00 | 2.00 | 2.27K | 879.00 | 2.10K | 8.28K | 43.20K | 864.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -273.00K | -200.00K |
| Income Before Tax | -847.83K | -939.83K | -1.57M | -1.63M | -2.41M | -55.74K | -54.90K | -56.71K | -64.61K | -106.32K | -61.81K | -142.98K | -59.60K | 11.89K | -28.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.37M | -2.24M |
| Income Before Tax Ratio | -39.68% | -46.72% | -52.80% | -36.82% | -26.04% | 0.46% | -0.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2.34% | -1.74% |
| Income Tax Expense | 0.00 | 9.37K | 723.00 | -203.44K | -500.90K | -4.14K | 785.59K | -22.82K | 0.00 | -2.27K | -880.00 | -2.10K | -925.00 | -346.00 | 0.00 | 27.87K | -16.96K | -15.00K | -7.00K | -2.00K | 32.00K | 4.80M | -910.00K | 2.28M |
| Net Income | -847.83K | -949.19K | -1.57M | -1.43M | -1.91M | -55.74K | -54.90K | -56.71K | -64.61K | -106.32K | -61.81K | -142.98K | -59.60K | 11.89K | -28.69K | -27.87K | 16.96K | 15.00K | 7.00K | 2.00K | -32.00K | -4.80M | -854.00K | -2.49M |
| Net Income Ratio | -39.68% | -47.19% | -52.83% | -32.24% | -20.62% | 0.46% | -0.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.84% | -1.94% |
| EPS | -1.41 | -1.58 | -2.62 | -2.38 | -3.42 | -1.23 | -1.63 | -1.69 | -1.92 | -3.17 | -1.84 | -4.50 | -1.95 | 0.39 | -0.94 | -0.91 | 0.56 | 0.49 | 0.23 | 0.07 | -1.05 | -157.18 | -27.95 | -81.56 |
| EPS Diluted | -1.41 | -1.58 | -2.62 | -2.38 | -3.42 | -1.23 | -1.63 | -1.69 | -1.92 | -3.17 | -1.84 | -4.50 | -1.95 | 0.39 | -0.94 | -0.91 | 0.56 | 0.49 | 0.23 | 0.07 | -1.05 | -157.18 | -27.95 | -81.56 |
| Weighted Avg Shares Out | 600.09K | 600.09K | 600.09K | 600.09K | 557.34K | 45.39K | 33.59K | 33.59K | 33.59K | 33.59K | 33.59K | 31.77K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K |
| Weighted Avg Shares Out (Dil) | 600.09K | 600.09K | 600.09K | 600.09K | 557.34K | 45.39K | 33.59K | 33.59K | 33.59K | 33.59K | 33.59K | 31.77K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K | 30.55K |
Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit
HONG KONG , Nov. 18, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso" or the "Company") is pleased to announce that Dr. Michelle Xia , the company's founder, chairwoman, president, and CEO, will attend Morgan Stanley's 23rd Asia Pacific Summit.
Morgan Stanley finally turns bullish on U.S. stocks as it says the S&P 500 could jump as high as 7,400
Better late than never? Morgan Stanley says it's now overweight U.S. stocks.
Morgan Creek Capital's Mark Yusko explains why Nvidia makes him nervous
Mark Yusko, Morgan Creek Capital Management CEO & CIO, joins ‘Fast Money' to discuss Nvidia as the world's largest publicly traded company by market cap is set to report earnings next week.
Morgan Stanley Declares Dividends on Its Preferred Stock
NEW YORK--(BUSINESS WIRE)--Morgan Stanley today declared a regular dividend on the outstanding shares of each of the following preferred stock issues: Floating Rate Non-Cumulative Preferred Stock, Series A - $358.35 per share (equivalent to $0.358347 per Depositary Share) 10 Percent...
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
On Thursday, Bluebird Bio Inc. BLUE reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents.
Goldman Sachs Vs. Morgan Stanley: Which Big Bank Is The Better Buy?
Goldman Sachs and Morgan Stanley are two of the largest investment banks, excelling in Wealth Management, M&A, Trading, and Brokerage. Despite frequent comparisons, the banks have distinct differences in their business plans, priorities, and strategic visions. GS has an incredible...
Here's Why Hold Strategy is Apt for Kinder Morgan Stock Now
KMI generates stable fee-based revenues from its vast network of midstream infrastructure. However, a slowdown in drilling activities might affect it.
10%+ Yields: Why Morgan Stanley Direct Lending Is The New Blackstone Secured Lending
BXSL has been one of the best-performing BDCs of the past few years. I think MSDL is poised to experience similar outperformance moving forward. In this article, I explain why.
Bayer AG (BAYZF) Q3 2024 Earnings Call Transcript
Bayer AG (OTCPK:BAYZF) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Bill Anderson - Chairman & CEO Wolfgang Nickl - CFO Julio Triana - President, Consumer Health Division Stefan Oelrich - President, Pharmaceuticals Division Rodrigo...
Home Depot's Earnings Beat Sets Conservative Tone for FY24, J.P. Morgan Predicts Slowing Deterioration Ahead
J. P. Morgan analyst Christopher Horvers expressed views on Home Depot, Inc. HD third-quarter earnings results reported today.
Source: https://incomestatements.info
Category: Stock Reports